drugset / Trial / NCT03091868
Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics
RandomizedSequentialDouble-blindTreatment
Summary
To investigate the effect of rising oral single-doses of BIA 6-512 (25 mg, 50 mg, 100 mg and 200 mg) on levodopa pharmacokinetics when administered in combination with a single-dose of immediate release levodopa/carbidopa 100/25 mg (Sinemet® 100/25) or with a single-dose of Sinemet® 100/25 plus a single-dose of entacapone (Comtan®) 200 mg and to assess the tolerability and safety of rising single oral doses of BIA 6-512 when administered in combination with a single-dose of Sinemet® 100/25 or with a single-dose of Sinemet® 100/25 plus a single-dose of Comtan® 200 mg.
Timeline
- Start
- 2004-11-03
- Primary completion
- 2005-02-28
- Completion
- 2005-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resveratrol | Small molecule | 25 mg | Oral |
| Subject | Resveratrol | Small molecule | 50 mg | Oral |
| Subject | Resveratrol | Small molecule | 100 mg | Oral |
| Subject | Resveratrol | Small molecule | 200 mg | Oral |
| Background | Entacapone | Small molecule | 200 mg | Oral |
| Background | levodopa/carbidopa | Unknown | 25 mg | Oral |
| Background | levodopa/carbidopa | Unknown | 100 mg | Oral |